Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sanofi-Aventis spins off Novexel

Executive Summary

Sanofi-Aventis has spun off a new anti-infectives company it will call Novexel, which has received €40mm ($53mm) in venture funding. The investors, which hold a 66% interest in the company, were led by Atlas Venture and included Sofinnova Partners, 3i, and Novo AS. Sanofi-Aventis retains a 22% stake.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Spin-Off
    • Venture Financing

Related Companies